{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:08:46Z","timestamp":1783926526837,"version":"3.55.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82504831"],"award-info":[{"award-number":["82504831"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030104,81874050,81572326,82473939,82441037"],"award-info":[{"award-number":["82030104,81874050,81572326,82473939,82441037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007848","name":"FDU | Institutes of Biomedical Sciences, Fudan University","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100007848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018625","name":"STCSM | Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","doi-asserted-by":"publisher","award":["20JC1410700"],"award-info":[{"award-number":["20JC1410700"]}],"id":[{"id":"10.13039\/501100018625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018625","name":"STCSM | Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","doi-asserted-by":"publisher","award":["24YF2706600"],"award-info":[{"award-number":["24YF2706600"]}],"id":[{"id":"10.13039\/501100018625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010031","name":"\u4e2d\u56fd\u535a\u58eb\u540e\u79d1\u5b66\u57fa\u91d1\u4f1a\u804c | Postdoctoral Research Foundation of China","doi-asserted-by":"publisher","award":["2024M760544,2025T180966,GZB20250822"],"award-info":[{"award-number":["2024M760544,2025T180966,GZB20250822"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2024ZD0525800"],"award-info":[{"award-number":["2024ZD0525800"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CD3 ligand 1 (CD3L1, ITPRIPL1), an emerging immune checkpoint, sustains immune privilege in the testis and facilitates tumor immune evasion. Targeting CD3L1 with a monoclonal antibody demonstrates potent antitumor activity in preclinical models and spontaneous tumors in companion animals. In an ongoing clinical trial, anti-CD3L1 therapy unexpectedly activated tumor-associated macrophages (TAMs) within the tumor microenvironment (TME), surpassing its anticipated role in T-cell reactivation. Mechanistic studies identified neuropilin-2 (NRP2) as the primary receptor on macrophages and uncovered the CD3L1-NRP2 axis as a critical driver of immunosuppressive M2 TAM polarization. Strikingly, in T-cell-deficient osteosarcoma models, anti-CD3L1 treatment reprogrammed TAMs toward an anti-tumor M1 phenotype, suppressing tumor progression. Clinical data corroborated these findings, revealing profound TME remodeling in advanced solid tumors. Our results elucidate a dual role for CD3L1 in immune evasion, mediated through both T-cell suppression and macrophage polarization, and highlight anti-CD3L1 as a multifaceted therapeutic strategy that enhances antigen presentation via TAM modulation.<\/jats:p>","DOI":"10.1038\/s44321-026-00451-3","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:09:56Z","timestamp":1778857796000},"page":"2635-2666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting CD3L1-NRP2 disarms myeloid-driven tumor immune evasion"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8662-2272","authenticated-orcid":false,"given":"Shouyan","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-9291","authenticated-orcid":false,"given":"Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5631-8958","authenticated-orcid":false,"given":"Jieyuan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chushu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3945-2536","authenticated-orcid":false,"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6443-5105","authenticated-orcid":false,"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"451_CR1","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.ccell.2023.09.001","volume":"41","author":"I Ausejo-Mauleon","year":"2023","unstructured":"Ausejo-Mauleon I, Labiano S, De La Nava D, Laspidea V, Zalacain M, Marrodan L, Garcia-Moure M, Gonzalez-Huarriz M, Hervas-Corpion I, Dhandapani L et al (2023) TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell 41:1911\u20131926.e8","journal-title":"Cancer Cell"},{"key":"451_CR2","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41586-024-07529-3","volume":"630","author":"JE Bader","year":"2024","unstructured":"Bader JE, Wolf MM, Lupica-Tondo GL, Madden MZ, Reinfeld BI, Arner EN, Hathaway ES, Steiner KK, Needle GA, Hatem Z et al (2024) Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature 630:968\u2013975","journal-title":"Nature"},{"key":"451_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.omto.2021.09.005","volume":"23","author":"M Billerhart","year":"2021","unstructured":"Billerhart M, Schonhofer M, Schueffl H, Polzer W, Pichler J, Decker S, Taschauer A, Maier J, Anton M, Eckmann S et al (2021) CD47-targeted cancer immunogene therapy: secreted SIRPalpha-Fc fusion protein eradicates tumors by macrophage and NK cell activation. Mol Ther Oncolytics 23:192\u2013204","journal-title":"Mol Ther Oncolytics"},{"key":"451_CR4","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.devcel.2024.07.017","volume":"59","author":"A Bond","year":"2024","unstructured":"Bond A, Fiaz S, Rollins K, Nario JEQ, Snyder ET, Atkins DJ, Rosen SJ, Granados A, Dey SS, Wilson MZ et al (2024) Prior Fc receptor activation primes macrophages for increased sensitivity to IgG via long-term and short-term mechanisms. Dev Cell 59:2882\u20132896.e7","journal-title":"Dev Cell"},{"key":"451_CR5","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1158\/1078-0432.CCR-10-2047","volume":"17","author":"EP Buddingh","year":"2011","unstructured":"Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC et al (2011) Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res 17:2110\u20132119","journal-title":"Clin Cancer Res"},{"key":"451_CR6","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/cac2.12607","volume":"44","author":"J Cai","year":"2024","unstructured":"Cai J, Song L, Zhang F, Wu S, Zhu G, Zhang P, Chen S, Du J, Wang B, Cai Y et al (2024) Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma. Cancer Commun 44:1231\u20131260","journal-title":"Cancer Commun"},{"key":"451_CR7","doi-asserted-by":"publisher","first-page":"e002022","DOI":"10.1136\/jitc-2020-002022","volume":"9","author":"X Cao","year":"2021","unstructured":"Cao X, Li B, Chen J, Dang J, Chen S, Gunes EG, Xu B, Tian L, Muend S, Raoof M et al (2021) Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. J Immunother Cancer 9:e002022","journal-title":"J Immunother Cancer"},{"key":"451_CR8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV (2021) Immune checkpoint inhibitors in melanoma. Lancet 398:1002\u20131014","journal-title":"Lancet"},{"key":"451_CR9","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R et al (2022) PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 386:2363\u20132376","journal-title":"N Engl J Med"},{"key":"451_CR10","doi-asserted-by":"publisher","first-page":"e006020","DOI":"10.1136\/jitc-2022-006020","volume":"11","author":"S Chen","year":"2023","unstructured":"Chen S, Lu K, Hou Y, You Z, Shu C, Wei X, Wu T, Shi N, Zhang G, Wu J et al (2023) YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6. J Immunother Cancer 11:e006020","journal-title":"J Immunother Cancer"},{"key":"451_CR11","doi-asserted-by":"publisher","first-page":"e55319","DOI":"10.7554\/eLife.55319","volume":"9","author":"H Danzer","year":"2020","unstructured":"Danzer H, Glaesner J, Baerenwaldt A, Reitinger C, Lux A, Heger L, Dudziak D, Harrer T, Gessner A, Nimmerjahn F (2020) Human Fcgamma-receptor IIb modulates pathogen-specific versus self-reactive antibody responses in Lyme arthritis. Elife 9:e55319","journal-title":"Elife"},{"key":"451_CR12","doi-asserted-by":"publisher","first-page":"1297211","DOI":"10.3389\/fcell.2023.1297211","volume":"11","author":"S Deng","year":"2023","unstructured":"Deng S, Shi J, Sun Y, Quan Y, Shen Z, Wang Y, Li H, Xu J (2023) Development of a monoclonal antibody to ITPRIPL1 for immunohistochemical diagnosis of non-small cell lung cancers: accuracy and correlation with CD8(+) T cell infiltration. Front Cell Dev Biol 11:1297211","journal-title":"Front Cell Dev Biol"},{"key":"451_CR13","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.cell.2024.03.019","volume":"187","author":"S Deng","year":"2024","unstructured":"Deng S, Zhang Y, Wang H, Liang W, Xie L, Li N, Fang Y, Wang Y, Liu J, Chi H et al (2024) ITPRIPL1 binds CD3epsilon to impede T cell activation and enable tumor immune evasion. Cell 187:2305\u20132323.e33","journal-title":"Cell"},{"key":"451_CR14","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/jcm13051446","volume":"13","author":"R Dhupar","year":"2024","unstructured":"Dhupar R, Powers AA, Eisenberg SH, Gemmill RM, Bardawil CE, Udoh HM, Cubitt A, Nangle LA, Soloff AC (2024) Orchestrating resilience: how neuropilin-2 and macrophages contribute to cardiothoracic disease. J Clin Med 13:1446","journal-title":"J Clin Med"},{"key":"451_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nm1332","volume":"12","author":"S Fichtner-Feigl","year":"2006","unstructured":"Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A (2006) IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 12:99\u2013106","journal-title":"Nat Med"},{"key":"451_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0092-8674(74)90050-6","volume":"3","author":"VH Freedman","year":"1974","unstructured":"Freedman VH, Shin SI (1974) Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 3:355\u2013359","journal-title":"Cell"},{"key":"451_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1161\/CIRCULATIONAHA.118.034165","volume":"139","author":"VC Ganta","year":"2019","unstructured":"Ganta VC, Choi M, Farber CR, Annex BH (2019) Antiangiogenic VEGF(165)b regulates macrophage polarization via S100A8\/S100A9 in peripheral artery disease. Circulation 139:226\u2013242","journal-title":"Circulation"},{"key":"451_CR18","doi-asserted-by":"publisher","first-page":"e000778","DOI":"10.1136\/jitc-2020-000778","volume":"8","author":"EM Garrido-Martin","year":"2020","unstructured":"Garrido-Martin EM, Mellows TWP, Clarke J, Ganesan AP, Wood O, Cazaly A, Seumois G, Chee SJ, Alzetani A, King EV et al (2020) M1(hot) tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. J Immunother Cancer 8:e000778","journal-title":"J Immunother Cancer"},{"key":"451_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1546-9","volume":"15","author":"M Genin","year":"2015","unstructured":"Genin M, Clement F, Fattaccioli A, Raes M, Michiels C (2015) M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer 15:577","journal-title":"BMC Cancer"},{"key":"451_CR20","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1097\/HEP.0000000000000690","volume":"79","author":"S Ghosh","year":"2024","unstructured":"Ghosh S, Devereaux MW, Liu C, Sokol RJ (2024) LRH-1 agonist DLPC through STAT6 promotes macrophage polarization and prevents parenteral nutrition-associated cholestasis in mice. Hepatology 79:986\u20131004","journal-title":"Hepatology"},{"key":"451_CR21","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1016\/j.cell.2021.07.029","volume":"184","author":"J Goc","year":"2021","unstructured":"Goc J, Lv M, Bessman NJ, Flamar AL, Sahota S, Suzuki H, Teng F, Putzel GG, Bank JRILC, Eberl G et al (2021) Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. Cell 184:5015\u20135030.e16","journal-title":"Cell"},{"key":"451_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccell.2023.12.011","volume":"42","author":"ET Goddard","year":"2024","unstructured":"Goddard ET, Linde MH, Srivastava S, Klug G, Shabaneh TB, Iannone S, Grzelak CA, Marsh S, Riggio AI, Shor RE et al (2024) Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell 42:119\u2013134.e12","journal-title":"Cancer Cell"},{"key":"451_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04671-6","volume":"13","author":"PK Govindappa","year":"2022","unstructured":"Govindappa PK, Elfar JC (2022) Erythropoietin promotes M2 macrophage phagocytosis of Schwann cells in peripheral nerve injury. Cell Death Dis 13:245","journal-title":"Cell Death Dis"},{"key":"451_CR24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","volume":"627","author":"X Guan","year":"2024","unstructured":"Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, Mcginnis L, Hendricks R, Nutsch K, Banta KL et al (2024) Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells. Nature 627:646\u2013655","journal-title":"Nature"},{"key":"451_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","volume":"185","author":"M Guilliams","year":"2022","unstructured":"Guilliams M, Bonnardel J, Haest B, Vanderborght B, Wagner C, Remmerie A, Bujko A, Martens L, Thone T, Browaeys R et al (2022) Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell 185:379\u2013396.e38","journal-title":"Cell"},{"key":"451_CR26","doi-asserted-by":"publisher","first-page":"121137","DOI":"10.1016\/j.biomaterials.2021.121137","volume":"278","author":"GR Gunassekaran","year":"2021","unstructured":"Gunassekaran GR, Poongkavithai, Vadevoo SM, Baek MC, Lee B (2021) M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials 278:121137","journal-title":"Biomaterials"},{"key":"451_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg2697","volume":"9","author":"S Han","year":"2023","unstructured":"Han S, Bao X, Zou Y, Wang L, Li Y, Yang L, Liao A, Zhang X, Jiang X, Liang D et al (2023) d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Sci Adv 9:eadg2697","journal-title":"Sci Adv"},{"key":"451_CR28","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.ccell.2023.05.004","volume":"41","author":"S Haston","year":"2023","unstructured":"Haston S, Gonzalez-Gualda E, Morsli S, Ge J, Reen V, Calderwood A, Moutsopoulos I, Panousopoulos L, Deletic P, Carreno G et al (2023) Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer. Cancer Cell 41:1242\u20131260.e6","journal-title":"Cancer Cell"},{"key":"451_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41420-021-00700-z","volume":"7","author":"F He","year":"2021","unstructured":"He F, Ding G, Jiang W, Fan X, Zhu L (2021) Effect of tumor-associated macrophages on lncRNA PURPL\/miR-363\/PDZD2 axis in osteosarcoma cells. Cell Death Discov 7:307","journal-title":"Cell Death Discov"},{"key":"451_CR30","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1007\/s00262-021-03136-7","volume":"71","author":"L He","year":"2022","unstructured":"He L, Bai Y, Xia L, Pan J, Sun X, Zhu Z, Ding J, Qi C, Tang C (2022) Oral administration of a whole glucan particle (WGP)-based therapeutic cancer vaccine targeting macrophages inhibits tumor growth. Cancer Immunol Immunother 71:2007\u20132028","journal-title":"Cancer Immunol Immunother"},{"key":"451_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-4939-7837-3_12","volume":"1784","author":"X Huang","year":"2018","unstructured":"Huang X, Li Y, Fu M, Xin HB (2018) Polarizing macrophages in vitro. Methods Mol Biol 1784:119\u2013126","journal-title":"Methods Mol Biol"},{"key":"451_CR32","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","volume":"184","author":"K Koikawa","year":"2021","unstructured":"Koikawa K, Kibe S, Suizu F, Sekino N, Kim N, Manz TD, Pinch BJ, Akshinthala D, Verma A, Gaglia G et al (2021) Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell 184:4753\u20134771.e27","journal-title":"Cell"},{"key":"451_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.addr.2015.11.009","volume":"99","author":"Y Komohara","year":"2016","unstructured":"Komohara Y, Fujiwara Y, Ohnishi K, Takeya M (2016) Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 99:180\u2013185","journal-title":"Adv Drug Deliv Rev"},{"key":"451_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1161\/CIRCRESAHA.123.324011","volume":"134","author":"P Kumar Jha","year":"2024","unstructured":"Kumar Jha P, Aikawa M, Aikawa E (2024) Macrophage heterogeneity and efferocytosis: beyond the M1\/M2 dichotomy. Circ Res 134:186\u2013188","journal-title":"Circ Res"},{"key":"451_CR35","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41586-024-07499-6","volume":"630","author":"K Li","year":"2024","unstructured":"Li K, Chatterjee A, Qian C, Lagree K, Wang Y, Becker CA, Freeman MR, Murali R, Yang W, Underhill DM (2024a) Profiling phagosome proteins identifies PD-L1 as a fungal-binding receptor. Nature 630:736\u2013743","journal-title":"Nature"},{"key":"451_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/path.6221","volume":"262","author":"T Li","year":"2024","unstructured":"Li T, Ran J, Miao Z, Yang M, Mou D, Jiang Y, Xu X, Xie Q, Jin K (2024b) Deficiency of inflammation-sensing protein neuropilin-2 in myeloid-derived macrophages exacerbates colitis via NF-kappaB activation. J Pathol 262:175\u2013188","journal-title":"J Pathol"},{"key":"451_CR37","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.7150\/thno.101107","volume":"14","author":"Q Lin","year":"2024","unstructured":"Lin Q, Olkowski CP, Choyke PL, Sato N (2024) Tumor growth suppression in adoptive T cell therapy via IFN-gamma targeting of tumor vascular endothelial cells. Theranostics 14:6897\u20136912","journal-title":"Theranostics"},{"key":"451_CR38","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2024.03.009","volume":"42","author":"M Liu","year":"2024","unstructured":"Liu M, Ren Y, Zhou Z, Yang J, Shi X, Cai Y, Arreola AX, Luo W, Fung KM, Xu C et al (2024) The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Cancer Cell 42:885\u2013903.e4","journal-title":"Cancer Cell"},{"key":"451_CR39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"G Lo Russo","year":"2019","unstructured":"Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V et al (2019) Antibody-Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade. Clin Cancer Res 25:989\u2013999","journal-title":"Clin Cancer Res"},{"key":"451_CR40","first-page":"185","volume":"35","author":"L Lopez-Sanz","year":"2023","unstructured":"Lopez-Sanz L, Bernal S, Jimenez-Castilla L, Pardines M, Hernandez-Garcia A, Blanco-Colio L, Martin-Ventura JL, Gomez Guerrero C (2023) The presence of activating IgG Fc receptors in macrophages aggravates the development of experimental abdominal aortic aneurysm. Clin Investig Arterioscler 35:185\u2013194","journal-title":"Clin Investig Arterioscler"},{"key":"451_CR41","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41420-025-02626-2","volume":"11","author":"X Lu","year":"2025","unstructured":"Lu X, Zhang X, Zhang F, Wang W, Liu R, Hou Y, Shi W, Li J, Peng C (2025) SPON2 facilitates osteosarcoma development by inducing M2 macrophage polarization through activation of the NF-kappaB\/VEGF signaling axis. Cell Death Discov 11:352","journal-title":"Cell Death Discov"},{"key":"451_CR42","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/249564a0","volume":"249","author":"WJ Martin","year":"1974","unstructured":"Martin WJ, Martin SE (1974) Naturally occurring cytotoxic anti-tumour antibodies in sera of congenitally athymic (nude) mice. Nature 249:564\u2013565","journal-title":"Nature"},{"key":"451_CR43","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s43018-023-00598-9","volume":"4","author":"Y Mei","year":"2023","unstructured":"Mei Y, Wang X, Zhang J, Liu D, He J, Huang C, Liao J, Wang Y, Feng Y, Li H et al (2023) Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response. Nat Cancer 4:1273\u20131291","journal-title":"Nat Cancer"},{"key":"451_CR44","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza MR, Chase DM, Slomovitz BM, Depont Christensen R, Novak Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM et al (2023) Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med 388:2145\u20132158","journal-title":"N Engl J Med"},{"key":"451_CR45","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cell.2022.01.008","volume":"185","author":"G Morad","year":"2022","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA (2022) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 185:576","journal-title":"Cell"},{"key":"451_CR46","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.addr.2017.04.010","volume":"114","author":"C Ngambenjawong","year":"2017","unstructured":"Ngambenjawong C, Gustafson HH, Pun SH (2017) Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev 114:206\u2013221","journal-title":"Adv Drug Deliv Rev"},{"key":"451_CR47","doi-asserted-by":"crossref","unstructured":"Ni H, Reitman ZJ, Zou W, Akhtar MN, Paul R, Huang M, Zhang D, Zheng H, Zhang R, Ma R et al (2025) FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy. Nat Cancer 6:460\u2013473","DOI":"10.1038\/s43018-025-00905-6"},{"key":"451_CR48","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1016\/j.cell.2021.04.038","volume":"184","author":"A Obradovic","year":"2021","unstructured":"Obradovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, Guo XV, Aggen DH, Rathmell WK, Jonasch E et al (2021) Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell 184:2988\u20133005.e16","journal-title":"Cell"},{"key":"451_CR49","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/glycob\/cwq216","volume":"21","author":"A Rey-Gallardo","year":"2011","unstructured":"Rey-Gallardo A, Delgado-Martin C, Gerardy-Schahn R, Rodriguez-Fernandez JL, Vega MA (2011) Polysialic acid is required for neuropilin-2a\/b-mediated control of CCL21-driven chemotaxis of mature dendritic cells and for their migration in vivo. Glycobiology 21:655\u2013662","journal-title":"Glycobiology"},{"key":"451_CR50","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.1158\/0008-5472.CAN-18-0562","volume":"78","author":"S Roy","year":"2018","unstructured":"Roy S, Bag AK, Dutta S, Polavaram NS, Islam R, Schellenburg S, Banwait J, Guda C, Ran S, Hollingsworth MA et al (2018) Macrophage-derived neuropilin-2 exhibits novel tumor-promoting functions. Cancer Res 78:5600\u20135617","journal-title":"Cancer Res"},{"key":"451_CR51","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.molimm.2017.08.010","volume":"90","author":"S Schellenburg","year":"2017","unstructured":"Schellenburg S, Schulz A, Poitz DM, Muders MH (2017) Role of neuropilin-2 in the immune system. Mol Immunol 90:239\u2013244","journal-title":"Mol Immunol"},{"key":"451_CR52","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL et al (2023) Immune checkpoint therapy-current perspectives and future directions. Cell 186:1652\u20131669","journal-title":"Cell"},{"key":"451_CR53","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jhep.2020.10.035","volume":"74","author":"S Stein","year":"2021","unstructured":"Stein S, Henze L, Poch T, Carambia A, Krech T, Preti M, Schuran FA, Reich M, Keitel V, Fiorotto R et al (2021) IL-17A\/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. J Hepatol 74:919\u2013930","journal-title":"J Hepatol"},{"key":"451_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9523","volume":"6","author":"S Su","year":"2015","unstructured":"Su S, Zhao Q, He C, Huang D, Liu J, Chen F, Chen J, Liao JY, Cui X, Zeng Y et al (2015) miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program. Nat Commun 6:8523","journal-title":"Nat Commun"},{"key":"451_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08106-w","volume":"16","author":"Z Tao","year":"2025","unstructured":"Tao Z, Zou P, Yang Z, Xiong T, Deng Z, Chen Q (2025) Targeting TIMM23 to overcome osteosarcoma chemoresistance. Cell Death Dis 16:856","journal-title":"Cell Death Dis"},{"key":"451_CR56","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2024.04.011","volume":"42","author":"MJ Van Elsas","year":"2024","unstructured":"Van Elsas MJ, Middelburg J, Labrie C, Roelands J, Schaap G, Sluijter M, Tonea R, Ovcinnikovs V, Lloyd K, Schuurman J et al (2024) Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell 42:1032\u20131050.e10","journal-title":"Cancer Cell"},{"key":"451_CR57","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.4049\/jimmunol.1601515","volume":"198","author":"E Vergadi","year":"2017","unstructured":"Vergadi E, Ieronymaki E, Lyroni K, Vaporidi K, Tsatsanis C (2017) Akt signaling pathway in macrophage activation and M1\/M2 polarization. J Immunol 198:1006\u20131014","journal-title":"J Immunol"},{"key":"451_CR58","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","volume":"58","author":"J Waibl Polania","year":"2025","unstructured":"Waibl Polania J, Hoyt-Miggelbrink A, Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, Lerner E, Woroniecka K, Finlay JB, Ayasoufi K et al (2025) Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity 58:232\u2013246.e6","journal-title":"Immunity"},{"key":"451_CR59","doi-asserted-by":"crossref","unstructured":"Wang J, Cao W, Huang J, Zhou Y, Zheng R, Lou Y, Yang J, Yan J, Tang J, Ye M et al (2026) Tumor-associated CD19(+) macrophages induce immunosuppressive microenvironment in hepatocellular carcinoma. Nat Commun 17:3250","DOI":"10.1038\/s41467-026-69638-z"},{"key":"451_CR60","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","volume":"176","author":"J Wang","year":"2019","unstructured":"Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W et al (2019) Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell 176:334\u2013347.e12","journal-title":"Cell"},{"key":"451_CR61","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn8402","volume":"11","author":"X Wang","year":"2025","unstructured":"Wang X, Li Y, Li Y, Wang X, Song H, Wang Y, Huang C, Mao C, Wang L, Zhong C et al (2025) AMPK-dependent Parkin activation suppresses macrophage antigen presentation to promote tumor progression. Sci Adv 11:eadn8402","journal-title":"Sci Adv"},{"key":"451_CR62","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s10020-023-00702-w","volume":"29","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wan R, Hu C (2023) Leptin\/obR signaling exacerbates obesity-related neutrophilic airway inflammation through inflammatory M1 macrophages. Mol Med 29:100","journal-title":"Mol Med"},{"key":"451_CR63","doi-asserted-by":"publisher","first-page":"112575","DOI":"10.1016\/j.yexcr.2021.112575","volume":"402","author":"Y Wei","year":"2021","unstructured":"Wei Y, Liang M, Xiong L, Su N, Gao X, Jiang Z (2021) PD-L1 induces macrophage polarization toward the M2 phenotype via Erk\/Akt\/mTOR. Exp Cell Res 402:112575","journal-title":"Exp Cell Res"},{"key":"451_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202002054","volume":"32","author":"Y Xia","year":"2020","unstructured":"Xia Y, Rao L, Yao H, Wang Z, Ning P, Chen X (2020) Engineering macrophages for cancer immunotherapy and drug delivery. Adv Mater 32:e2002054","journal-title":"Adv Mater"},{"key":"451_CR65","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s41565-022-01225-x","volume":"17","author":"K Yang","year":"2022","unstructured":"Yang K, Han W, Jiang X, Piffko A, Bugno J, Han C, Li S, Liang H, Xu Z, Zheng W et al (2022a) Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration. Nat Nanotechnol 17:1322\u20131331","journal-title":"Nat Nanotechnol"},{"key":"451_CR66","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.tips.2020.08.003","volume":"41","author":"Y Yang","year":"2020","unstructured":"Yang Y, Guo J, Huang L (2020) Tackling TAMs for cancer immunotherapy: it\u2019s nano time. Trends Pharm Sci 41:701\u2013714","journal-title":"Trends Pharm Sci"},{"key":"451_CR67","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L (2025) Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Exp Clin Cancer Res 44:145","journal-title":"J Exp Clin Cancer Res"},{"key":"451_CR68","doi-asserted-by":"publisher","first-page":"109121","DOI":"10.1016\/j.diabres.2021.109121","volume":"184","author":"Y Yang","year":"2022","unstructured":"Yang Y, Zhang B, Yang Y, Peng B, Ye R (2022b) FOXM1 accelerates wound healing in diabetic foot ulcer by inducing M2 macrophage polarization through a mechanism involving SEMA3C\/NRP2\/Hedgehog signaling. Diab Res Clin Pr 184:109121","journal-title":"Diab Res Clin Pr"},{"key":"451_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202103675","volume":"9","author":"W Yao","year":"2022","unstructured":"Yao W, Chen Y, Li Z, Ji J, You A, Jin S, Ma Y, Zhao Y, Wang J, Qu L et al (2022) Single cell RNA sequencing identifies a unique inflammatory macrophage subset as a druggable target for alleviating acute kidney injury. Adv Sci 9:e2103675","journal-title":"Adv Sci"},{"key":"451_CR70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.omto.2020.11.003","volume":"20","author":"M Zalacain","year":"2021","unstructured":"Zalacain M, Bunuales M, Marrodan L, Labiano S, Gonzalez-Huarriz M, Martinez-Velez N, Laspidea V, Puigdelloses M, Garcia-Moure M, Gonzalez-Aparicio M et al (2021) Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma. Mol Ther Oncolytics 20:23\u201333","journal-title":"Mol Ther Oncolytics"},{"key":"451_CR71","doi-asserted-by":"publisher","first-page":"106268","DOI":"10.1016\/j.intimp.2020.106268","volume":"81","author":"L Zhang","year":"2020","unstructured":"Zhang L, Li W, Sun Y, Li X, Kong L, Xu P, Xia P, Yue J (2020) Activation of activating Fc gamma receptors down-regulates the levels of interferon beta, interferon gamma and interferon lambda1 in porcine alveolar macrophages during PRRSV infection. Int Immunopharmacol 81:106268","journal-title":"Int Immunopharmacol"},{"key":"451_CR72","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-24-1454","volume":"30","author":"L Zhang","year":"2024","unstructured":"Zhang L, Maalouf A, Makri SC, Banerjee J, Suru A, Tam AJ, Calizo A, Pollard K, Wang J, Danilova L et al (2024) Multidimensional immunotyping of human NF1-associated peripheral nerve sheath tumors uncovers tumor-associated macrophages as key drivers of immune evasion in the tumor microenvironment. Clin Cancer Res 30:5459\u20135472","journal-title":"Clin Cancer Res"},{"key":"451_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58429-7","volume":"16","author":"N Zhang","year":"2025","unstructured":"Zhang N, Sun L, Zhou S, Ji C, Cui T, Chu Q, Ye J, Liang S, Ma K, Liu Y et al (2025) Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation. Nat Commun 16:3177","journal-title":"Nat Commun"},{"key":"451_CR74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205085120","volume":"120","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Song Q, Cassady K, Lee M, Tang H, Zheng M, Wang B, Schones DE, Fu YX, Riggs AD et al (2023) Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proc Natl Acad Sci USA 120:e2205085120","journal-title":"Proc Natl Acad Sci USA"},{"key":"451_CR75","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/glycob\/cwab111","volume":"32","author":"JY Zhou","year":"2022","unstructured":"Zhou JY, Zhou D, Telfer K, Reynero K, Jones MB, Hambor J, Cobb BA (2022a) Antigen presenting cell response to polysaccharide A is characterized by the generation of anti-inflammatory macrophages. Glycobiology 32:136\u2013147","journal-title":"Glycobiology"},{"key":"451_CR76","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.ccell.2022.10.012","volume":"40","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Chen MM, Luo Y, Mojumdar K, Peng X, Chen H, Kumar SV, Akbani R, Lu Y, Liang H (2022b) Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. Cancer Cell 40:1324\u20131340.e8","journal-title":"Cancer Cell"},{"key":"451_CR77","doi-asserted-by":"publisher","first-page":"e004219","DOI":"10.1136\/jitc-2021-004219","volume":"10","author":"X Zhu","year":"2022","unstructured":"Zhu X, Liang R, Lan T, Ding D, Huang S, Shao J, Zheng Z, Chen T, Huang Y, Liu J et al (2022) Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer. J Immunother Cancer 10:e004219","journal-title":"J Immunother Cancer"},{"key":"451_CR78","doi-asserted-by":"publisher","first-page":"105037","DOI":"10.1016\/j.cellimm.2025.105037","volume":"418","author":"F Zou","year":"2025","unstructured":"Zou F, Zhang Y, Wang M, Quan Y, Ping H (2025) Macrophages: traffic centers in the tumor immune microenvironment. Cell Immunol 418:105037","journal-title":"Cell Immunol"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00451-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00451-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00451-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:31:36Z","timestamp":1783924296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00451-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":78,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,13]]}},"alternative-id":["451"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00451-3","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The related patent (WO2022089557, entitled \u201cUse of regulator of CD3L1 in preparation of drug that regulates immune responses or fights tumors\u201d) has been licensed to BioTroy Therapeutics. Jie Xu is the scientific founder of BioTroy Therapeutics. Xiaolin Zhou and Huanbin Wang work for BioTroy Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}